Statera Biopharma Inc. (NASDAQ:STAB) currently has a daily average trading volume of 3.01M but it saw 3765602 shares traded on Wednesday. With a market cap of 5.51M USD, stock’s current market price of $0.10 came rising about 6.45 while comparing to the previous closing price of $0.10. In past 52 weeks, the stock remained buoying in the range of price level as high as $3.60 and as low as $0.09. In the recent trading on the day, stock has struck highest price mark of $0.114 while lowest mark touched by it was $0.097.
Taking a look at 20-day trading activity of Statera Biopharma Inc. (STAB) gives us an average price of $0.1181, while its current price level is -97.11% below from 52-week high level whereas it is 10.05% above from lowest level seen by the stock during that period. Simple moving average of 50 days or SMA-50 of the stock’s closing price is $0.1414 while that of 200 days or SMA-200 reads an average of $0.2916. A closer look into the stock’s movement over the week reveals that its volatility is standing at 9.38% during that period while stretching the period over a month that increases to 14.87%. It is also necessary to take a look into other indicators of a stock too, to get a better idea about its price movement. And in doing so, we find stock’s 14-day relative strength index (RSI) standing at 41.25 which implies that the stock is in neutral territory.
Statera Biopharma Inc. (STAB)’s stock is currently under the radar of 1 analysts who are in consensus at a 12-month price target range of between $40.00 and $40.00 for company’s shares. The average price target assigned by the average number of analysts to a stock is a way to gauge worth of any stock in next 52 weeks. And in assigning price target to a stock, some analysts adopt a bearish approach by advocating lower-than-average price target which in this case is $40.00 while some adopt bullish approach by assigning higher-than-average price target which reads the price to top $40.00. Average price target assigned by them is $40.00 which highlights an upside potential of 99.75% for the stock over that period. And to attain the median price target of $40.00 assigned by those analysts, stock has to add about 99.75% of value to its current levels.
Data by FactSet Research shows that 1 analysts have issued their ratings for the stock. 0 of them are in opinions that stock is a Sell, while 0 are advising it as an Overweight. 0 analysts suggested the investors to Buy the stock while 1 advised them to Hold.
Over the week, STAB’s stock price is moving 2.97% up while it is -25.55% when we observe its performance for the past one month. Year-to-date it is -95.48% down and over the past year, the stock is showing a downside performance of -96.98%.
The company is expected to be releasing its next quarterly report in 02/20/2023, for which analysts forecasted an EPS of $0 while estimate for next year EPS is $0.
Currently, Statera Biopharma Inc.’s total number of outstanding shares is 53.30M with 17.16% of that held by the insiders while 6.18% of its common stock has been owned by the institutions. Company’s return on investment (ROI) stands at -715.60%. Stock’s beta reads 1.00. Stock has a price to sale or P/S ratio amounts to 1.67.
In the most recent quarter, SunAmerica Series Trust – SA T Ro came rising its stake by 423.08% in the company and now holds 61200.0 or 0.12% of the company’s stake having worth of about 8568.0.